Literature DB >> 25083975

The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*.

Labib Debiane1, Ray Y Hachem, Iba Al Wohoush, William Shomali, Ramez R Bahu, Ying Jiang, Anne-Marie Chaftari, Joseph Jabbour, Munirah Al Shuaibi, Alexander Hanania, S Egbert Pravinkumar, Philipp Schuetz, Issam Raad.   

Abstract

OBJECTIVES: Infections in critically ill patients continue to impose diagnostic and therapeutic challenges. We seek to investigate the utility of proadrenomedullin and procalcitonin as diagnostic and prognostic biomarkers in febrile critically ill patients with cancer and compare their performance with that of C-reactive protein.
DESIGN: Single-center prospective cohort study.
SETTING: Tertiary care, academic, university hospital. PATIENTS: One hundred fourteen critically ill patients with cancer with fever.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Blood samples were withdrawn on the day of fever onset and 4 to 7 days thereafter, and the serum proadrenomedullin, procalcitonin, and C-reactive protein levels were measured using the Kryptor technology afterward. Of the 114 adult patients, 27 had bloodstream infections, 36 had localized infections, and the remaining had no infections. The area under the receiver operating characteristic curve for bloodstream infection diagnosis was significantly greater for proadrenomedullin (0.70; 95% CI, 0.59-0.82) and procalcitonin (0.71; 95% CI, 0.60-0.83) compared with C-reactive protein (0.53; 95% CI, 0.39-0.66) (p = 0.021 and p = 0.003, respectively). Receiver operating characteristic analysis also showed that proadrenomedullin (p = 0.005) and procalcitonin (p = 0.009) each had a better performance than C-reactive protein in predicting patients' mortality within 2 months after their fever onset. Regarding patients' response to antimicrobial therapy, proadrenomedullin, procalcitonin, and C-reactive protein levels all significantly decreased from baseline to follow-up in responders (p ≤ 0.002), whereas only proadrenomedullin level significantly increased in nonresponders (p < 0.0001). In patients with documented infections, proadrenomedullin (0.81; 95% CI, 0.71-0.92) and procalcitonin (0.73; 95% CI, 0.60-0.85) each had a greater area under the curve compared with C-reactive protein (0.59; 95% CI, 0.45-0.73) as for as predicting response (p = 0.004 and p = 0.043, respectively). However, for all febrile patients, proadrenomedullin had a significantly greater area under the curve for predicting favorable response than procalcitonin (p < 0.0001).
CONCLUSION: In critically ill patients with cancer, proadrenomedullin and procalcitonin both have a promising role in predicting bloodstream infections in a manner more helpful than C-reactive protein. These two biomarkers were superior to C-reactive protein in the prognostic analysis of response to antimicrobial therapy for those patients with documented infections. However, proadrenomedullin was superior to procalcitonin in predicting response in all febrile patients and was unique in showing increased levels among nonresponders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25083975     DOI: 10.1097/CCM.0000000000000526

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  19 in total

1.  Leveraging Clinical Time-Series Data for Prediction: A Cautionary Tale.

Authors:  Eli Sherman; Hitinder Gurm; Ulysses Balis; Scott Owens; Jenna Wiens
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

Review 2.  New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.

Authors:  Francisco Valenzuela-Sánchez; Blanca Valenzuela-Méndez; Juan Francisco Rodríguez-Gutiérrez; Ángel Estella-García; María Ángela González-García
Journal:  Ann Transl Med       Date:  2016-09

Review 3.  Diagnosing sepsis - The role of laboratory medicine.

Authors:  Shu-Ling Fan; Nancy S Miller; John Lee; Daniel G Remick
Journal:  Clin Chim Acta       Date:  2016-07-04       Impact factor: 3.786

4.  Procalcitonin improves the Glasgow Prognostic Score for outcome prediction in emergency patients with cancer: a cohort study.

Authors:  Anna Christina Rast; Alexander Kutz; Susan Felder; Lukas Faessler; Deborah Steiner; Svenja Laukemann; Sebastian Haubitz; Andreas Huber; Ulrich Buergi; Antoinette Conca; Barbara Reutlinger; Beat Mueller; Mario Bargetzi; Philipp Schuetz
Journal:  Dis Markers       Date:  2015-03-15       Impact factor: 3.434

5.  Comparison of diagnostic and prognostic utility of lactate and procalcitonin for sepsis in adult cancer patients presenting to emergency department with systemic inflammatory response syndrome.

Authors:  Esra Keçe; Elif Yaka; Serkan Yılmaz; Nurettin Özgür Doğan; Cansu Alyeşil; Murat Pekdemir
Journal:  Turk J Emerg Med       Date:  2016-03-10

6.  Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients.

Authors:  Amanda G Blouin; Meier Hsu; Martin Fleisher; Lakshmi V Ramanathan; Stephen M Pastores
Journal:  Clin Chim Acta       Date:  2020-07-15       Impact factor: 3.786

7.  Mid-Regional Proadrenomedullin and Mid-Regional Proatrial Natriuretic Peptide Clearance Predicts Poor Outcomes Better Than Single Baseline Measurements in Critically Ill Patients With Pneumonia: A Retrospective Cohort Study.

Authors:  Jos Van Oers; Johannes Krabbe; Evelien Kemna; Yvette Kluiters; Piet Vos; Dylan De Lange; Armand Girbes; Albertus Beishuizen
Journal:  Cureus       Date:  2021-05-28

8.  Clinical Usefulness of Procalcitonin and C-Reactive Protein as Outcome Predictors in Critically Ill Patients with Severe Sepsis and Septic Shock.

Authors:  Jeong-Am Ryu; Jeong Hoon Yang; Daesang Lee; Chi-Min Park; Gee Young Suh; Kyeongman Jeon; Joongbum Cho; Sun Young Baek; Keumhee C Carriere; Chi Ryang Chung
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

9.  Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination.

Authors:  Silvia Angeletti; Giordano Dicuonzo; Marta Fioravanti; Marina De Cesaris; Marta Fogolari; Alessandra Lo Presti; Massimo Ciccozzi; Lucia De Florio
Journal:  Dis Markers       Date:  2015-11-09       Impact factor: 3.434

10.  Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia.

Authors:  Hanine El Haddad; Anne-Marie Chaftari; Ray Hachem; Majd Michael; Ying Jiang; Ammar Yousif; Sammy Raad; Mary Jordan; Patrick Chaftari; Issam Raad
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.